Vaxcyte announced on Monday that its VAX-31 pneumococcal vaccine met primary endpoints in a Phase 3 clinical trial involving just over 3,500 adults aged 50 and older. The vaccine covers 31 bacterial strains, positioning the California-based biotech to compete with Pfizer's 20-strain Prevnar and Merc